NYU Langone Health
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, NYU Langone Health sits in the top decile of US sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count).
NYU Langone Health: 1,164 sponsored US clinical trials, 197 recruiting.
NYU Langone Health sponsors 1,164 registered US clinical trials on ClinicalTrials.gov, 197 of them currently recruiting, and 741 completed. 123 of these trials are in Phase 3-4 (later-stage) and 231 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 12 trials.
Top-decile sponsor footprint
NYU Langone Health ranks in the top decile of sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
741 of 866 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,164 total, page 3 of 24
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
NCT05799378
Evaluating the Implementation of a Comprehensive Multilevel Virtual Oncology Program Among Veterans Diagnosed With Lung, Colorectal, Prostate, and Breast Cancers in the US Department of Veterans Affairs
NCT06559059
Pharyngeal Exercise (Plus Protein)
NCT05963113
Clinical Outcomes in Prostate Cancer Patients Undergoing HIFU Ablation
NCT07203482
Promoting Equitable Access to Language Services in Health and Human Services
NCT06272110
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
NCT06397703
MENTOR Wellness Program
NCT06148324
SilverCloud as a School-Based Intervention for Vulnerable Youth
NCT06004414
Safety and Efficacy of Empagliflozin in Hemodialysis
NCT05786443
Use of GeriKit to Better Phenotype Older Adults With Ischemic Heart Disease
NCT05788666
Perceptual Adaptation Following Cochlear Implantation (Aim 3a)
NCT07039435
Cleaner Air for Lower Cardiometabolic Risk
NCT05994937
Safety of the Herpes Zoster Subunit Vaccine in Lupus
NCT05559671
Reducing AIR Pollution Exposure to Lower Blood PRESSURE Among New York City Public Housing Residents
NCT05874479
Predictive Biomarker for Endoscopic Therapy in Chronic Pancreatitis
NCT06267365
E-cigarettes for Harm Reduction Among Smokers With Serious Mental Illness
NCT05815199
RELAXaHEAD for Headache Patients (Phase III)
NCT06077838
Persona MC vs PS RCT With ROSA
NCT05391828
Dynamic Airway CT is Diagnostic for Tracheomalacia in Children
NCT06028646
Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population
NCT05981183
Ladarixin With Sotorasib in Advanced NSCLC
NCT05815173
OurChild: A Health IT Solution to Reduce Minority Health Disparities
NCT04677647
Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy
NCT05591118
Two Fraction Prostate SBRT With DIL SIB
NCT05864196
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
NCT05984602
NYC Cancer Outreach Network in Neighborhoods for Equity and Community Translation
NCT05742178
Considering Racial and Acculturation Stress in Addressing Trauma
NCT05974176
Building Access to Food Through Systems and Solidarity
NCT05381766
Psilocybin Therapy in Advanced Cancer
NCT05398484
Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression - R33
NCT05573074
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
NCT05723107
World Trade Center Particulate Matter Induced Cardiorespiratory and Vascular Dysfunction: a MultiOmic Approach (CaRVD)
NCT05215171
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
NCT05757791
Innate Immunity Stimulation Via TLR9 in Early AD
NCT05606341
Evaluating a Noise Reduction Algorithm With Cochlear Implant Users
NCT05805384
Dietary and Cognitive Effects of Food Ads Posted by TikTok Influencers
NCT05777486
Assessing and Addressing Community Exposures to Environmental Contaminants
NCT06315140
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
NCT05428007
Leveraging Regulatory Flexibility for Methadone Take-Home Dosing to Improve Retention in Treatment for Opioid Use Disorder
NCT05675735
Integrating Financial Coaching and Smoking Cessation Coaching
NCT05154669
Cholesterol Lowering and Residual Risk in Diabetes, Type 1
NCT05641753
Advanced Diffusion Imaging in Renal Cancer Patients
NCT06116253
Gut Kidney Axis in Enteric Hyperoxaluria
NCT05124886
Decision Aid (DA) for Renal Patients
NCT05387863
Change in Stroke Volume Index After Diuresis for Patients With Decompensated Heart Failure
NCT05240651
Optimized MRI of Patients With Hip Arthroplasty
NCT04875884
Effects of Stellate Ganglion Block in Post-traumatic Stress Disorder
NCT05391971
Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis
NCT05020028
Paradoxical Lucidity in Severe End-Stage Dementia
NCT05234866
Working With Doctors and Pharmacists to Help Parents Give Children's Liquid Medicines Safely
NCT05146388
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 99 |
| Phase 2 | 132 |
| Phase 3 | 28 |
| Phase 4 | 95 |
Therapeutic Areas
What is open in the NYU Langone Health pipeline
197 recruiting of 1,164 indexed (17% open); 741 completed (64%).
Phase mix: 123 late (III/IV) vs 231 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
NYU Langone Health: open-pipeline peers nationwide
Peers matched on 1,164 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
NYU Langone Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,164 trials (± recruiting share)
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
- Wake Forest University Health Sciences · 1,140 trials · 15% recruiting
- Emory University · 1,208 trials · 17% recruiting
- Northwestern University · 1,209 trials · 15% recruiting
Sponsors near 17% open enrollment (± trial volume)
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
- University of Utah · 17% recruiting · 818 trials
Related
What to do with this NYU Langone Health page
1,164 registered trials is a research-attention snapshot, not an endorsement of NYU Langone Health or any single study.
- 197 of NYU Langone Health's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition NYU Langone Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
NYU Langone Health pipeline card: 1,164 registered trials from official public datasets.Report a data error.